Recent reports have indicated that serum sclerostin levels are elevated in Alzheimer’s disease in association with high brain amyloid β accumulation (Yuan et al., 2023), and osteocyte-derived sclerostin can traverse the BBB, leading to the accumulation of amyloid β and disease progression in AD model mice (Shi et al., 2024), further supporting the therapeutic potential of the Wnt/β-catenin pathway in Alzheimer’s disease. Here, SOST is linked to early-onset autosomal dominant Alzheimer disease.